

IDEAL4RWE – the RWE Training Programme in DIGICORE

Iwona Ługowska and James Anderson

November 13, 2023




Objectives for today

45	(Re-) introduction to IDEAL4RWE	10 mins
8 8999	Study team presentations	30 mins
	Reflections and lessons learned	10 mins
	Next steps – announcing a new training programme	10 mins
		DigiCore


1

What does it take for DIGICORE to succeed in its mission?



2

IDEAL4RWE is a first-of-its kind skills and leadership development programme



3

Training

Team activity

This has been a substantial programme, and feedback has been excellent

The story in numbers

- 47 participants signed up for phase 1
- 4 seminars delivered on RWE technical content
- 4 teams self-organised and working on studies
- 3 teams awarded €210k funding by IQVIA (LAB decision)
- **2 "leadership retreats"** in Paris (Sept '22) and Frankfurt (March '23)
- 2 conference abstracts submitted
- Overall feedback received
 - "How likely to recommend?" 8.8/10
 - "Net promoter score" 62%





I'm very impressed with the programme... I have learned a lot about myself and how I relate to others in meetings and my work environment **Data Scientist**



the topics [covered]...made it possible to think critically through our own project/process Clinician



We are grateful for the input and collaboration of our leadership advisory board



Prof David Cameron (Edinburgh University) – Co-chair



Prof Iwona Lugowska (Oncology Institute, Poland) – Co-chair



Prof Massimo di Maio (Oncology Department, Turin)



Prof Janne Vehreschild (German Centre for Infection Research)



Dr Sue Cheeseman (Leeds Teaching Hospital)



Dr Anne-Sophie Hamy-Petit (University of Paris)



Prof Andre Dekker (Maastricht Comprehensive Cancer Centre)



Gilliosa Spurrier Bernard (Co-chair WECAN)



Dr Mariana Guergova-Kuras (IQVIA)



James Anderson (DIGICORE)





TEAM PRESENTATIONS

Breast





TEAM PRESENTATIONS

Head and Neck






TEAM PRESENTATIONS

Prostate



What we learned: planned vs. actual patient numbers



)igi(ore


Q&A





Questions for the teams, the organisers or the Leadership Advisory Board





DigiCore

Announcement: 2 training programmes to support i3

1 MEDOC/ ETL training

To upskill <u>hospital IT</u> <u>staff and data scientists</u> to extract and configure data to MEDOC OMOP standard for cancer studies



Z IDEAL40MOP

To give <u>early career</u> researchers (clinical and <u>non-clinical)</u> the skills they need to design and run cancer OMOP studies

Funding from i3 award budget, with additional contributions from IQVIA



1) MEDOC/ ETL training scope and approach

္ဂ ^{င္ာ} Who?	 C. 30 Hospital IT staff and data scientists SQL familiarity (but OMOP not needed) – could be clinician with coding skills or high-performing IT team member
? What?	 Training on basics of OMOP and MEDOC Light-touch support in building a cancer OMOP instance in their hospital
How?	 Virtual seminars basics of OMOP/ MEDOC (Q1-2, 2024) In-person training event (aligned w/ OHDSI 2024 tbc) Light touch peer-peer support
_C ⁷ When?	 Q1 2024 (recruitment) Q2 2024 (seminars/ training) Q3-Q4 2024 (light touch support)
泛 T&Cs?	 i3 hospital (travel funded by grant) Other organisations (need to fund travel)

Aims

By July 2024:

- A cohort of 30+ OMOP trained hospital IT staff, leading inhospital implementation
- A library of open source tools/ documentation for use by other hospitals (built off existing implementation guide)

By end 2024 and beyond:

• **Expanded** number of DIGICORE members with basic OMOP instance (suitable for e.g., counts)



DRAFT

2) IDEAL4OMOP scope and approach

္က ^O Who?	 Under 45yr clinicians, data scientists etc. Want to lead OMOP enabled oncology research
? What?	 Training on both technical and leadership skills Delivery of an international proof-of-concept study
How?	 Mix of training styles: Face-to-face and virtual Funding available (can cover backfill) Advisory board oversight and allocation of funding
. When?	 Recruitment and free introductory programme in Q1-2 2024 RWE studies start in Q4 2024, conclude Q4 2025
全 T&Cs?	 Cancer OMOP instance in place (or planned with funding) For backfill study funding: centre must be DIGICORE member. Others can participate – but no funding Balance of different tumour types (solid/ haem/ rare)




 Increased awareness of DIGICORE



DRAFT

Indicative timeline for IDEAL4OMOP Cohort



DRAFT

Target audience for IDEAL4OMOP, and what's in it for them?

Target clinician (statistician/ epi) is research interested (but not research obsessed)

% clinicians in Cancer centre X



What is in it for them?

- Seed funding & training for pilot studies
- International peers in their disease (= HORIZON team ready)
- Deep methods expertise from partners
- Secretarial / coordination support



A unique opportunity to create large scale, <u>fundable</u> outcomes research consortia

We need your help: We are starting recruitment now!

If you or colleagues are interested in learning more:

- Expressions of interest to training@digicore-cancer.eu
- Speak to a member of the DIGICORE team
- Look out for introductory seminars coming soon



